AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386

July 21, 2014

DUBLIN & LEXINGTON, Mass.--()--J

Seres Health Completes Enrollment in a Clinical Study for SER-109 in Recurrent Clostridium difficile Infection and Announces Positive Preliminary Data

Seres Health Completes Enrollment in a Clinical Study for SER-109 in Recurrent Clostridium difficile Infection and Announces Positive Preliminary Data

July 16, 2014

SER-109 demonstrated remarkably high clinical cure rate and excellent safety profile

Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity

Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity

July 16, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDA

Acceleron Pharma Appoints Terrence C. Kearney to its Board of Directors

Acceleron Pharma Appoints Terrence C. Kearney to its Board of Directors

July 14, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 14, 2014-- Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the appointment of Terrence C. Kearney to its Board of Directors and to the position of Chair of the Audit Committee.

Flagship Ventures Adds Pharma Industry Veteran Roger J. Pomerantz, M.D., F.A.C.P. as Senior Partner

Flagship Ventures Adds Pharma Industry Veteran Roger J. Pomerantz, M.D., F.A.C.P. as Senior Partner

July 14, 2014

CAMBRIDGE, Mass., /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on healthcare and sustainability, today announced the appointment of Roger J. Pomerantz, M.D., F.A.C.P., as a Senior Partner. In this role, Dr. Pomerantz will provide strategic counsel and support to the Flagship team as well as to portfolio companies through board and advisory roles. Dr. Pomerantz recently joined as President and Chief Executive Officer of Seres Health, a Flagship VentureLabs™-founded company.

Concert Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for CTP-499

Concert Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for CTP-499

July 8, 2014

--Provides Direction for Phase 3 Development in Diabetic Nephropathy--

Seres Health Announces Allowance for Key Patent on the Use of Synergistic Bacterial Compositions

Seres Health Announces Allowance for Key Patent on the Use of Synergistic Bacterial Compositions

July 7, 2014

Company's Breakthrough Innovation to Enable First Therapeutics for Microbiome-based Diseases

CAMBRIDGE, Mass., July 7, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pharmaceutical composition patent application that covers its lead product candidate, SER-109, which is currently in clinical testing for the treatment of recurrent C. difficile.

Joule First to Gain US EPA Clearance for Commercial Use of Modified Cyanobacteria for Fuel Production

Joule First to Gain US EPA Clearance for Commercial Use of Modified Cyanobacteria for Fuel Production

July 1, 2014

Bedford, MA – July 1, 2014 – Joule today announced that the US Environmental Protection Agency (EPA) has favorably reviewed the company’s Microbial Commercial Activity Notice (MCAN) for Joule’s first commercial ethanol-producing catalyst. This clears the catalyst for commercial use at the company’s demonstration plant in Hobbs, New Mexico. Notably, this also marks the first time that EPA has allowed the commercial use of a modified cyanobacterium.